VRCAVerrica Pharmaceuticals Inc.

$56M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+10240.5% YoY

Gross Profit

$3M70.3% margin

Operating Income

-$19M-486.1% margin

Net Income

-$20M-531.4% margin

EPS (Diluted)

$-4.37

QoQ Revenue Growth

+92.5%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$66M

Total Liabilities

$65M

Stockholders' Equity

$2M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$37,000	+10240.5%
Gross Profit	$3M	-$31,000	+8771.0%
Operating Income	-$19M	-$7M	-162.4%
Net Income	-$20M	-$7M	-208.6%

Revenue Segments

Product

$3M84%

Collaboration

$594,00016%

VRCA Q1 2024 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena